Mylan’s Lower-Cost EpiPen May Not Hurt Drugmaker’s Sales Much
- Company offers half-price generic after drug price firestorm
- Drugmaker has said generic will make shot more affordable
Mylan Plans Half-Priced Generic Version of EpiPen
This article is for subscribers only.
Selling a version of its market-leading EpiPen at half the price of the original may not hurt Mylan NV very much, according to analysts who track the company.
The drugmaker responded to outrage about price increases for the allergy shot by announcing Monday that it would introduce a generic version for $300 -- while also continuing to sell the branded product. Mylan gives away about half of the $600 brand-name price in rebates, discounts and fees. It may give up far less, as a proportion of the price, on the generic version, said analysts.